Alzheimer's disease and immunotherapy

Aging and Disease

Volumn 4, Issue 4, 2013, Pages 210-220

  Madeo, Jennifer ^a   Frieri, Marianne ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Immunosenescence; Immunotherapy; Monoclonal antibodies; Vaccination

Indexed keywords

EID: 84896549278     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Martin Prince RB, Cleusa Ferri (2011) World Alzheimer Report 2011. Vol. 2013, Alzheimer's Disease International, London
2. Leuner K, Muller WE and Reichert AS (2012). From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol Neurobiol, 46: 186-193
3. Alonso-Fernandez P and De la Fuente M (2011). Role of the immune system in aging and longevity. Curr Aging Sci, 4: 78-100
4. Letiembre M, Hao W, Liu Y, Walter S, Mihaljevic I, Rivest S, Hartmann T and Fassbender K (2007). Innate immune receptor expression in normal brain aging. Neuroscience, 146: 248-254
5. Di Napoli M and Shah IM (2011). Neuroinflammation and cerebrovascular disease in old age: a translational medicine perspective. J Aging Res, 2011: 857484
6. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D and Perry VH (2003). Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry, 74: 788-789
7. You Z, Luo C, Zhang W, Chen Y, He J, Zhao Q, Zuo R and Wu Y (2011). Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav Brain Res, 225: 135-141
8. Stump TE, Callahan CM and Hendrie HC (2001). Cognitive impairment and mortality in older primary care patients. J Am Geriatr Soc, 49: 934-940
9. Ginaldi L, Loreto MF, Corsi MP, Modesti M and De Martinis M (2001). Immunosenescence and infectious diseases. Microbes Infect, 3: 851-857
10. Godbout JP and Johnson RW (2009). Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol Allergy Clin North Am, 29: 321-337
11. Banks WA (1999). Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol, 5: 538-555
12. Mallard C (2012). Innate immune regulation by toll-like receptors in the brain. ISRN Neurol, 2012: 701950
13. Fung A, Vizcaychipi M, Lloyd D, Wan Y and Ma D (2012). Central nervous system inflammation in disease related conditions: mechanistic prospects. Brain Res, 1446: 144-155
14. Buchanan JB, Sparkman NL, Chen J and Johnson RW (2008). Cognitive and neuroinflammatory consequences of mild repeated stress are exacerbated in aged mice. Psychoneuroendocrinology, 33: 755-765
15. Pagani L and Eckert A (2011). Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis, 2011: 925050
16. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A and Muller WE (2009). Mitochondrial dysfunction: an early event inAlzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging, 30: 1574-1586
17. Ye SM and Johnson RW (2001). An age-related decline in interleukin-10 may contribute to the increased expression of interleukin-6 in brain of aged mice. Neuroimmunomodulation, 9: 183-192
18. Cameron B, Tse W, Lamb R, Li X, Lamb BT and Landreth GE (2012). Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease. J Neurosci, 32: 15112-15123
19. Verri M, Pastoris O, Dossena M, Aquilani R, Guerriero F, Cuzzoni G, Venturini L, Ricevuti G and Bongiorno AI (2012). Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Int J Immunopathol Pharmacol, 25: 345-353
20. Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E and Ricevuti G (2011). Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev, 11: 149-153
21. Tarawneh R and Holtzman DM (2012). The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med, 2: a006148
22. Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y and Tenner AJ (2011). Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflammation, 8: 4
23. Daborg J, Holmgren S, Abramsson A, Andreasson U, Zetterberg M, Nilsson S, Minthon L, Skoog I, Blennow K, Pekna M, Hanse E and Zetterberg H (2013). Complement Gene Single Nucleotide Polymorphisms and Biomarker Endophenotypes of Alzheimer's Disease. J Alzheimers Dis
24. Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wilson RS, Tran D, Aubin C, Buchman AS, Heward CB, Myers AJ, Hardy JA, Huentelman MJ, Corneveaux JJ, Reiman EM, Evans DA, Bennett DA and De Jager PL (2011). CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol, 69: 560-569
25. Crehan H, Holton P, Wray S, Pocock J, Guerreiro R and Hardy J (2012). Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology, 217: 244-250
26. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE and Jack CR, Jr. (2009). Mild cognitive impairment: ten years later. Arch Neurol, 66: 1447-1455
27. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S and Phelps CH (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7: 263-269
28. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jonhagen M, Minthon L, Winblad B, Blennow K and Zetterberg H (2012). Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 78: 468-476
29. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW and Trojanowski JQ (2012). The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement, 8: S1-68
30. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H and Blennow K (2008). Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement, 4: 38-48
31. Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C and Lovestone S (2011). Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One, 6: e28527
32. Kosicek M and Hecimovic S (2013). Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers. Int J Mol Sci, 14: 1310-1322
33. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R and Grundman M (2010). 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol, 9: 363-372
34. Hardy J and Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297: 353-356
35. Fu HJ, Liu B, Frost JL and Lemere CA (2010). Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets, 9: 197-206
36. Tabira T (2010). Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med, 220: 95-106
37. Cribbs DH (2010). Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets, 9: 207-216
38. Wilcock DM and Colton CA (2008). Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis, 15: 555-569
39. Wilcock DM, Zhao Q, Morgan D, Gordon MN, Everhart A, Wilson JG, Lee JE and Colton CA (2011). Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro, 3: 249-258
40. Wisniewski T and Sigurdsson EM (2010). Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta, 1802: 847-859
41. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P and Hutton M (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet, 25: 402-405
42. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N and Cattaneo A (2000). Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci U S A, 97: 6826-6831
43. Delrieu J, Ousset PJ, Caillaud C and Vellas B (2012). 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem, 120 Suppl 1: 186-193
44. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D and Seubert P (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400: 173-177
45. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M and Arendash GW (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408: 982-985
46. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P and Westaway D (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 408: 979-982
47. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM and Ervin FR (2004). Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol, 165: 283-297
48. Ghochikyan A, Davtyan H, Petrushina I, Hovakimyan A, Movsesyan N, Davtyan A, Kiyatkin A, Hannaman D, Evans CF, Cribbs DH and Agadjanyan MG (2013). Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother, 9
49. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D and Yednock T (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med, 6: 916-919
50. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S and Ashe KH (2002). Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci, 22: 6331-6335
51. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN and Morgan D (2004). Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation, 1: 24
52. Lemere CA, Maier M, Jiang L, Peng Y and Seabrook TJ (2006). Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res, 9: 77-84
53. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P and Yednock T (2003). Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A, 100: 2023-2028
54. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM and DeMattos RB (2005). Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci, 25: 629-636
55. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN and Morgan D (2006). Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci, 26: 5340-5346
56. Li Y, Ma Y, Zong LX, Xing XN, Guo R, Jiang TZ, Sha S, Liu L and Cao YP (2012). Intranasal inoculation with an adenovirus vaccine encoding ten repeats of Abeta3-10 reduces AD-like pathology and cognitive impairment in Tg-APPswe/PSEN1dE9 mice. J Neuroimmunol, 249: 16-26
57. Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D and Pilotto A (2012). Immunotherapy for Alzheimer's disease: from anti-beta-amyloid to tau-based immunization strategies. Immunotherapy, 4: 213-238
58. Sigurdsson EM (2009). Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res, 6: 446-450
59. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D and Buee L (2012). Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res, 9: 397-405
60. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB and Donoghue S (2005). Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology, 64: 94-101
61. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M and Grundman M (2009). Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res, 6: 144-151
62. Robinson SR, Bishop GM, Lee HG and Munch G (2004). Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging, 25: 609-615
63. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L and Koller M (2005). Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 64: 1563-1572
64. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E and Nicoll JA (2008). Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 372: 216-223
65. Ryan JM and Grundman M (2009). Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis, 17: 243
66. Chackerian B (2010). Virus-like particle based vaccines for Alzheimer disease. Hum Vaccin, 6: 926-930
67. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM and Graf A (2012). Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol, 11: 597-604
68. Kingwell K (2012). Alzheimer disease: Amyloid-beta immunotherapy CAD106 passes first safety test in patients with Alzheimer disease. Nat Rev Neurol, 8: 414
69. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F and Schmidt W (2009). Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing. J Nutr Health Aging, 13: 264-267
70. Robert R and Wark KL (2012). Engineered antibody approaches for Alzheimer's disease immunotherapy. Arch Biochem Biophys, 526: 132-138
71. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M and Liu E (2012). Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol, 69: 1002-1010
72. Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A and Solfrizzi V (2010). Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy, 2: 767-782
73. Grundman M, Dibernardo A, Raghavan N, Krams M and Yuen E (2013). 2012: A watershed year for Alzheimer's disease research. J Nutr Health Aging, 17: 51-53
74. Delrieu J, Ousset PJ and Vellas B (2012). Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther, 12: 1077-1086
75. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S and Morris JC (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med, 367: 795-804
76. Freeman GB, Lin JC, Pons J and Raha NM (2012). 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis, 28: 531-541
77. Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB, Jr., Bales K, Alvey C, McCush F, Yang J, Kupiec JW and Bednar MM (2013). Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease: A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study. Clin Neuropharmacol, 36: 14-23
78. Guan X, Zou J, Gu H and Yao Z (2012). Short amyloid-beta immunogens with spacer-enhanced immunogenicity without junctional epitopes for Alzheimer's disease immunotherapy. Neuroreport, 23: 879-884
79. Weksler ME, Gouras G, Relkin NR and Szabo P (2005). The immune system, amyloid-beta peptide, and Alzheimer's disease. Immunol Rev, 205: 244-256
80. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R and Weksler ME (2009). 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging, 30: 1728-1736
81. Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Jeffreys M, Davis S, Thokala P and Moxham T (2013). Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age Ageing, 42: 14-20
82. Jaturapatporn D, Isaac MG, McCleery J and Tabet N (2012). Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev, 2: CD006378
83. von Bernhardi R (2010). Immunotherapy in Alzheimer's disease: where do we stand? Where should we go? J Alzheimers Dis, 19: 405-421
84. Wang W, Fan L, Xu D, Wen Z, Yu R and Ma Q (2012). Immunotherapy for Alzheimer's disease. Acta Biochim Biophys Sin (Shanghai), 44: 807-814
85. Aisen PS and Vellas B (2013). Editorial: passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? J Nutr Health Aging, 17: 49-50
86. Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M, Muniz AL and Vega JA (2011). Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Curr Pharm Des, 17: 508-520
87. Mayeux R and Schupf N (2011). Blood-based biomarkers for Alzheimer's disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging, 32 Suppl 1: S10-19
88. Glat MJ and Offen D (2013). Cell and gene therapy in Alzheimer's disease. Stem Cells Dev
89. Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH and Hutton ML (2012). A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron, 76: 908-920
90. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM and Siemers ER (2012). Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement, 8: 261-271
91. Tabira T, Matsumoto SE and Jin H (2011). [Antibody therapy for Alzheimer's disease]. Rinsho Shinkeigaku, 51: 1160-1161